[go: up one dir, main page]

RS65943B1 - Režim doziranja anti-bcma agenasa - Google Patents

Režim doziranja anti-bcma agenasa

Info

Publication number
RS65943B1
RS65943B1 RS20241032A RSP20241032A RS65943B1 RS 65943 B1 RS65943 B1 RS 65943B1 RS 20241032 A RS20241032 A RS 20241032A RS P20241032 A RSP20241032 A RS P20241032A RS 65943 B1 RS65943 B1 RS 65943B1
Authority
RS
Serbia
Prior art keywords
bcma
agents
dosing regimen
regimen
dosing
Prior art date
Application number
RS20241032A
Other languages
English (en)
Inventor
Julia Stieglmaier
Birgit Huber
Alexander Minella
Vijay Upreti
Original Assignee
Amgen Res Munich Gmbh
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68581157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS65943(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Res Munich Gmbh, Amgen Inc filed Critical Amgen Res Munich Gmbh
Publication of RS65943B1 publication Critical patent/RS65943B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RS20241032A 2019-11-11 2019-11-11 Režim doziranja anti-bcma agenasa RS65943B1 (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19208417.6A EP3819007B1 (en) 2019-11-11 2019-11-11 Dosing regimen for anti-bcma agents

Publications (1)

Publication Number Publication Date
RS65943B1 true RS65943B1 (sr) 2024-10-31

Family

ID=68581157

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20241032A RS65943B1 (sr) 2019-11-11 2019-11-11 Režim doziranja anti-bcma agenasa
RS20240493A RS65581B1 (sr) 2019-11-11 2020-05-08 Režim doziranja za anti-bcma agense

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20240493A RS65581B1 (sr) 2019-11-11 2020-05-08 Režim doziranja za anti-bcma agense

Country Status (19)

Country Link
US (1) US20210139584A1 (sr)
EP (3) EP3819007B1 (sr)
JP (1) JP2022554362A (sr)
AU (1) AU2020381671A1 (sr)
CA (1) CA3155069A1 (sr)
DK (2) DK3819007T3 (sr)
ES (2) ES2987783T3 (sr)
FI (2) FI3819007T3 (sr)
HR (2) HRP20241281T1 (sr)
HU (2) HUE068401T2 (sr)
LT (2) LT3819007T (sr)
MX (1) MX2022005628A (sr)
PL (2) PL3819007T3 (sr)
PT (2) PT3819007T (sr)
RS (2) RS65943B1 (sr)
SI (2) SI3819007T1 (sr)
SM (2) SMT202400373T1 (sr)
TW (1) TW202118784A (sr)
WO (1) WO2021094000A1 (sr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022103781A1 (en) * 2020-11-10 2022-05-19 Amgen Inc. Methods for administering a bcma x cd3 binding molecule
WO2023098846A1 (zh) * 2021-12-03 2023-06-08 江苏先声药业有限公司 抗bcma纳米抗体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233A (en) 1837-06-14 Improvement in plows
US4447A (en) 1846-04-04 Car- wheel
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
WO1999054440A1 (en) 1998-04-21 1999-10-28 Micromet Gesellschaft Für Biomedizinische Forschung Mbh CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
ATE251181T1 (de) 1998-07-28 2003-10-15 Micromet Ag Heterominikörper
JP4948174B2 (ja) 2003-10-16 2012-06-06 マイクロメット アクツィエン ゲゼルシャフト 多重特異的脱免疫ｃｄ３−結合物質
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
RU2561457C2 (ru) 2007-04-03 2015-08-27 Эмджен Рисерч (Мьюник) Гмбх Cd3-эпсилон-связывающий домен с межвидовой специфичностью
CA2721202A1 (en) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
EP3421491A3 (en) 2009-10-30 2019-03-27 Albumedix Ltd Albumin variants
WO2012059486A1 (en) 2010-11-01 2012-05-10 Novozymes Biopharma Dk A/S Albumin variants
JP2014500879A (ja) * 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
BR112013028536A2 (pt) 2011-05-05 2016-11-29 Novozymes Biopharma Dk As variantes de albumina
EP3892640A1 (en) 2011-08-23 2021-10-13 Roche Glycart AG Bispecific t cell activating antigen binding molecules
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
ES2664328T3 (es) 2012-03-16 2018-04-19 Albumedix A/S Variantes de albúmina
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
CA2903258C (en) 2013-03-15 2019-11-26 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US20160257748A1 (en) 2013-09-25 2016-09-08 Amgen Inc. V-c-fc-v-c antibody
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
HRP20241757T1 (hr) 2015-04-13 2025-02-28 Pfizer Inc. Terapijska protutijela i njihova upotreba
US10683369B2 (en) 2015-08-03 2020-06-16 Engmab Sàrl Monoclonal antibodies against BCMA
UA127515C2 (uk) 2015-08-17 2023-09-20 Янссен Байотек, Інк. Антитіло до всма, біспецифічна антигензв'язувальна молекула, що зв'язує всма і cd3, і їх використання
KR20240118898A (ko) * 2016-02-03 2024-08-05 암젠 리서치 (뮌헨) 게엠베하 Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
EP3535295A1 (en) 2016-11-02 2019-09-11 EngMab Sàrl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
KR102569133B1 (ko) 2017-10-13 2023-08-21 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
PT3796912T (pt) 2018-05-23 2023-05-17 Celgene Corp Compostos antiproliferativos e anticorpo biespecífiico contra bcma e cd3 para uso combinado
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
MA53732A (fr) * 2018-09-28 2022-01-05 Amgen Inc Anticorps dirigés contre bcma soluble
AU2020207962A1 (en) * 2019-01-18 2021-07-22 University Of Southern California Methods and compositions to improve the safety and efficacy of cellular therapies
KR20220024729A (ko) 2019-06-24 2022-03-03 노파르티스 아게 B-세포 성숙 항원을 표적으로 하는 다중특이성 항체에 대한 투여 요법 및 병용 요법
DK3766701T3 (da) 2019-07-18 2023-07-03 Barberan Latorre Jesus Francisco Hoved, maskine og fremgangsmåde til digital udskrivning på underlag
MX2022005292A (es) 2019-11-05 2022-08-10 Bristol Myers Squibb Co Metodos de tratamiento con anticuerpos contra bcma y cd3.
JP2023542257A (ja) * 2020-09-16 2023-10-05 アムジェン インコーポレイテッド 癌の治療のために二重特異性ｔ細胞誘導分子の治療用量を投与する方法
WO2022103781A1 (en) * 2020-11-10 2022-05-19 Amgen Inc. Methods for administering a bcma x cd3 binding molecule

Also Published As

Publication number Publication date
FI4058148T3 (fi) 2024-05-06
DK4058148T5 (da) 2024-07-22
RS65581B1 (sr) 2024-06-28
JP2022554362A (ja) 2022-12-28
EP3819007B1 (en) 2024-07-10
SI3819007T1 (sl) 2024-10-30
LT3819007T (lt) 2024-10-10
HUE068401T2 (hu) 2024-12-28
SMT202400373T1 (it) 2024-11-15
SMT202400165T1 (it) 2024-05-14
SI4058148T1 (sl) 2024-06-28
EP4058148B1 (en) 2024-03-13
PT4058148T (pt) 2024-05-03
HRP20240553T1 (hr) 2024-07-05
MX2022005628A (es) 2022-06-14
PL3819007T3 (pl) 2024-11-18
PT3819007T (pt) 2024-09-20
ES2987070T3 (es) 2024-11-13
EP4424709A2 (en) 2024-09-04
PL4058148T3 (pl) 2024-09-16
EP4424709A3 (en) 2024-12-11
HRP20241281T1 (hr) 2024-12-06
FI3819007T3 (fi) 2024-09-25
LT4058148T (lt) 2024-05-27
EP4058148A1 (en) 2022-09-21
EP3819007A1 (en) 2021-05-12
US20210139584A1 (en) 2021-05-13
DK4058148T3 (da) 2024-05-06
AU2020381671A1 (en) 2022-03-31
TW202118784A (zh) 2021-05-16
CA3155069A1 (en) 2021-05-20
DK3819007T3 (da) 2024-09-30
WO2021094000A1 (en) 2021-05-20
HUE066166T2 (hu) 2024-07-28
ES2987783T3 (es) 2024-11-18

Similar Documents

Publication Publication Date Title
PL3347054T3 (pl) Schematy dawkowania koniugatów przeciwciało anty-TF-lek
GB201713653D0 (en) Dosage regimen
CA194973S (en) Package
HUE066166T2 (hu) ANTI-BCMA hatóanyagok adagolási rendje
EP4054636A4 (en) DOSAGE SCHEME FOR ANTI-DLL3 ACTIVES
IL291432A (en) Dosage for anti-tryptase antibodies
IL280515A (en) Dosing regimens for algolix
PL3733041T3 (pl) Urządzenie dozujące
EP4055061A4 (en) DOSAGE SCHEME FOR ANTI-EGFRVIII ACTIVE INGREDIENTS
GB2588686B (en) Chemical-agent dosing apparatus
IL274375A (en) Dosing regimen of edsalonacant for the treatment of muscular dystrophy
IL288078A (en) Eltrombopag dosing regimen
GB201902454D0 (en) Dosage regimen
GB201910963D0 (en) Dosing unit
GB201903654D0 (en) Dosing device
IL308095A (en) Dosing regimens
GB201720519D0 (en) Dosing regimen
GB201718106D0 (en) Dosing regimen
GB201919139D0 (en) Easier-opening packages
GB201718000D0 (en) Dosing regimen
GB201717694D0 (en) Dosing regimen
GB201906594D0 (en) Dosing system
CA191469S (en) Package
CA207713S (en) Package
CA207714S (en) Package